Sort   by:  
 Page size 
UnknownBEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
Not available
S-EPMC4500832 | biostudies-literature
UnknownL-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.
Not available
S-EPMC3478577 | biostudies-literature
UnknownPhase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Not available
S-EPMC4451172 | biostudies-literature
UnknownProspective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer.
Not available
S-EPMC3383175 | biostudies-literature
UnknownEfficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Not available
S-EPMC3675695 | biostudies-literature
TranscriptomicsTranscription profiling of mouse prostate from AKT transgenic or wild type littermate controls treated with RAD001 (MTOR inhibition) or placebo reveals mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways reveals
Transgenic (Probasin driven Myr-AKT)or wild-type littermates were treated with RAD001 or placebo and sacrificed at 12 and 48 hours following the beginning of treatment
ORGANISM(S): Mus musculus 
2007-09-29 | E-GEOD-1413 | biostudies-arrayexpress
Sort   by:  
 Page size